Fortis Memorial Research Institute (FMRI) in Gurugram, along with Agilus Diagnostics, has just launched their second Genexus system, taking a huge step in revolutionizing cancer care in India.

This new system is part of the country’s fastest-growing and most advanced rapid genomic testing program, designed to give patients the right treatment at the right time, based on their genetic makeup.  The Genexus platform uses the latest technology, Next-Generation Sequencing (NGS), which can provide critical test results much faster than traditional methods. For example, Liquid Biopsy results now come in just 24 hours, Myeloid NGS in 72 hours, and Minimal Residual Disease (MRD) testing takes only five days.

This is a huge improvement compared to older methods, which often took weeks and didn’t provide the deep insight doctors need to understand the complexities of cancer.  Dr. Rahul Bhargava, a top doctor at FMRI, shared how this new system is a game-changer for cancer care.

With the addition of the second Genexus system, they can now help even more patients with blood cancers like leukemia, getting faster test results that lead to better treatment decisions. According to Dr. Bhargava, genomics—the study of genes—is not just a “future technology,” but a crucial tool in making sure patients get the best care possible. With faster and more precise insights, doctors can treat patients earlier and give them a better shot at long-term survival. 

This quick turnaround in test results is already making a real difference for cancer patients. For instance, with faster results, doctors can now quickly match patients to the most effective, personalized treatments based on their genetic profile. This has led to a big jump in the number of patients receiving targeted therapies, from just 11% to over 40%. For patients needing bone marrow transplants, the waiting time has been cut from nearly four months to just under three months, which can make all the difference in recovery. Plus, earlier treatment decisions are saving lives—doctors have reduced the number of early deaths by more than half. 

Dr. Anand K, CEO of Agilus Diagnostics, is excited about how the second Genexus system is helping to make advanced cancer care more accessible to everyone. He said that the system isn’t just about fast results; it’s about giving doctors the tools they need to make quicker, smarter decisions for patients. With this collaboration, patients no longer have to wait unnecessarily for crucial test results. The partnership between Fortis and Agilus has brought together a team of experts—doctors, pathologists, and scientists—to ensure that no one misses out on life-saving treatments.

As the rollout of this technology continues to grow, it’s clear that Fortis and Agilus are leading the way in bringing fast, effective cancer care to more people across the country.

The addition of the second Genexus system is another step forward in making sure that cancer treatment is not only faster but also more personalized, offering hope to patients in need of urgent care. This technology is proving that with the right tools, we can make a real difference in the fight against cancer.